S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Oncimmune Share Forecast, Price & News

GBX 160
0.00 (0.00%)
(As of 01/19/2022 09:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.31 million shs
Average Volume
133,816 shs
Market Capitalization
£110.62 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

Oncimmune logo

About Oncimmune

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.


Oncimmune (LON:ONC) Stock Price Down 1.5%
January 15, 2022 |  americanbankingnews.com
Oncimmune Hldgs PLC : Results from COVID-19 autoantibody profiling panel
January 4, 2022 |  markets.businessinsider.com
Oncimmune Hldngs PLC : Grant of Options and PDMR Dealing
December 26, 2021 |  markets.businessinsider.com
Oncimmune Hldngs PLC : ImmunoINSIGHTS commercial update
December 22, 2021 |  markets.businessinsider.com
Oncimmune Hldngs PLC : PDMR Dealing
December 22, 2021 |  markets.businessinsider.com
Oncimmune Hldngs PLC : Notice of Full Year results
November 6, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Diagnostics & Research
Year Founded

Sales & Book Value

Annual Sales
£3.72 million
Cash Flow
GBX 12.58 per share
Book Value
GBX 7.60 per share


Pretax Margin




Free Float
Market Cap
£110.62 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)


Overall MarketRank

1.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Oncimmune (LON:ONC) Frequently Asked Questions

How has Oncimmune's stock been impacted by Coronavirus?

Oncimmune's stock was trading at GBX 70.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONC shares have increased by 127.0% and is now trading at GBX 160.
View which stocks have been most impacted by COVID-19

When is Oncimmune's next earnings date?

Oncimmune is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Oncimmune

How were Oncimmune's earnings last quarter?

Oncimmune Holdings plc (LON:ONC) issued its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The firm earned $0.08 million during the quarter.
View Oncimmune's earnings history

Who are Oncimmune's key executives?

Oncimmune's management team includes the following people:
  • Dr. Adam Mark Hill Ph.D., CEO & Director (Age 41, Pay $385k)
  • Mr. Matthew Hall, Chief Financial Officer
  • Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Chief Scientific Officer
  • Ms. Cléa Rosenfeld, Head of Investor Relations
  • Mr. Ron Kirschner, Gen. Counsel & Company Sec.
  • Dr. James R. Jett M.D., Chief Medical Officer of US
  • Mr. Maarten Brusse, Chief Commercial Officer of Asia
  • Mr. Shane Smith, Sr. VP of Market Access & Reimbursement Oncimmune (Usa)
  • Mr. Matthew Luttrell, Chief Commercial Officer
  • Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 54)

What other stocks do shareholders of Oncimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), (APHA), (AQB), Axsome Therapeutics (AXSM), (BGSF), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST).

What is Oncimmune's stock symbol?

Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."

How do I buy shares of Oncimmune?

Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oncimmune's stock price today?

One share of ONC stock can currently be purchased for approximately GBX 160.

How much money does Oncimmune make?

Oncimmune has a market capitalization of £110.62 million and generates £3.72 million in revenue each year.

How many employees does Oncimmune have?

Oncimmune employs 72 workers across the globe.

What is Oncimmune's official website?

The official website for Oncimmune is oncimmune.com.

Where are Oncimmune's headquarters?

How can I contact Oncimmune?

Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.